Innovent Biologics, Inc. (HKG:1801)

Innovent Biologics Revenue

Innovent Biologics had revenue of 5.95B CNY in the half year ending June 30, 2025, with 120.36% growth. This brings the company's revenue in the last twelve months to 11.42B, up 53.18% year-over-year. In the year 2024, Innovent Biologics had annual revenue of 9.42B with 51.82% growth.

• Revenue (ttm): 11.42B CNY
• Revenue Growth: +53.18%
• P/S Ratio: 11.56
• Revenue / Employee: 2.02M CNY
• Employees: 5,659
• Market Cap: 144.64B HKD

Revenue Chart

* This company reports financials in CNY.

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2024	9.42B	3.22B	51.82%
Dec 31, 2023	6.21B	1.65B	36.21%
Dec 31, 2022	4.56B	286.65M	6.71%
Dec 31, 2021	4.27B	425.91M	11.08%
Dec 31, 2020	3.84B	2.80B	266.94%